Decision to widen access to existing medicines and fund a new medicine for the treatment of cystic fibrosis

Pharmac has made a decision to widen access to Trikafta and Kalydeco, and to fund Alyftrek for the treatment of cystic fibrosis.From 1 April 2026, the following changes will be implemented for people with eligible mutations:

• Widened access to Trikafta (elexacaftor/tezacaftor/ivacaftor)

• Widened access to Kalydeco (ivacaftor)

• Funding of a new medicine, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor)

  
  

This decision follows consultation with people with cystic fibrosis, their families, healthcare professionals and advocacy groups. Feedback received helped inform and improve access settings for these medicines.You can read the full decision here: 

Decision to widen access to Trikafta and Kalydeco, and fund Alyftrek for the treatment of cystic fibrosis

Ngā mihi

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

P: 0800 660 050 | www.pharmac.govt.nz